Radiopharm Theranostics Limited (RAD.AX)
| Previous Close | 0.0360 |
| Open | 0.0360 |
| Bid | 0.0350 x N/A |
| Ask | 0.0370 x N/A |
| Day's Range | 0.0350 - 0.0360 |
| 52 Week Range | 0.0270 - 0.1464 |
| Volume | |
| Avg. Volume | 1,810,011 |
| Market Cap | 37.013M |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.62 |
GlobeNewswireRadiopharm Receives Strategic Investment for up to A$18 million
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024Option for Lantheus to invest a further A$7.5m within 6 months on the same termsLantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development agreement SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- Radiopharm The
- GlobeNewswire
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to commence its First-In-Human Phase I study in Australia for the Company’s therapy for patients with PDL1-positive non-small cell lung cancer (NSCLC). The dose escalation trial of RAD204, which targets PDL1-p
Simply Wall St.Radiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)
Radiopharm Theranostics ( ASX:RAD ) Full Year 2023 Results Key Financial Results Net loss: AU$34.6m (loss widened by...
